NEW YORK, July 13, 2017 /PRNewswire/ --
If you want a Stock Review on ATHX, AVEO, HTBX, or RXDX then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. On Wednesday, the NASDAQ Composite ended the day at 6,261.17, up 1.10%; the Dow Jones Industrial Average edged 0.57% higher, to finish at 21,532.14; and the
Cleveland, Ohio headquartered Athersys Inc.'s stock finished Wednesday's session 1.21% higher at $1.67 with a total trading volume of 570,684 shares. The Company's shares have advanced 13.61% in the past month, 12.08% in the previous three months, and 9.15% since the start of this year. The stock is trading 11.45% above its 50-day moving average and 9.14% above its 200-day moving average. Additionally, shares of Athersys, which focuses on the research and development activities in the field of regenerative medicine, have a Relative Strength Index (RSI) of 58.53. ATHX complete research report is just a click away and free at:
On Wednesday, shares in Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc. recorded a trading volume of 7.96 million shares, which was above their three months average volume of 4.75 million shares. The stock ended the session 1.70% lower at $2.89. The Company's shares have skyrocketed 283.75% in the last one month, 380.23% in the previous three months, and 435.19% on an YTD basis. The stock is trading 167.16% above its 50-day moving average and 266.94% above its 200-day moving average. Moreover, shares of AVEO Pharma, which develops targeted therapies for cancer and related diseases, have an RSI of 80.02. The complimentary report on AVEO can be downloaded at:
Durham, North Carolina-based Heat Biologics Inc.'s shares closed the day 0.02% higher at $0.55. The stock recorded a trading volume of 274,955 shares. The Company's shares are trading 17.22% below their 50-day moving average. Additionally, shares of Heat Biologics, which focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the US, have an RSI of 35.51. Sign up for your complimentary research report on HTBX at:
Shares in San Diego, California headquartered Ignyta Inc. finished 4.00% higher at $10.40. The stock recorded a trading volume of 1.20 million shares, which was above its three months average volume of 934,690 shares. The Company's shares have surged 28.40% in the last one month, 30.00% in the previous three months, and 96.23% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 25.32% and 45.34%, respectively. Furthermore, shares of Ignyta, which engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases, have an RSI of 60.46.
On June 22nd, 2017, research firm Jefferies resumed its 'Buy' rating on the Company's stock, with a target price of $27 per share. Get free access to your research report on RXDX at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Drug abuse is a negative social trend that pushes youth to drug addiction in the pretext of getting ...
Proper understanding of waste collection, segregation and management is required to reduce the ...
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...View All